Kyntra Bio Inc. (Kyntra) is a biopharmaceutical company focused on discovering, developing, and commercializing new therapies for major unmet needs in anemia, fibrotic diseases, and cancer. Its R&D platform is based on connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology, and it operates as a single business segment spanning discovery through commercialization.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Kyntra is focused on developing innovative, first-in-class therapies for chronic conditions and diseases that are life-threatening or significantly debilitating. Its research and development efforts center on progressing a portfolio of candidates, including roxadustat for anemia associated with chronic kidney disease, pamrevlumab for fibrotic and proliferative disorders, and FG-3246 for metastatic castration-resistant prostate cancer and other tumor types. To support long-term growth, the company actively advances and manages its clinical pipeline. Kyntra Bio Inc’s R&D organization oversees the full development process—conducting preclinical and clinical studies, pursuing regulatory approvals, and coordinating the manufacturing and supply of products and investigational candidates. These programs involve rigorous testing through extensive studies conducted in accordance with U.S. FDA requirements and comparable regulations in other countries, with the goal of assessing the safety and efficacy of new therapies. In FY2025, the company incurred R&D expenses of US$23.5 million.